<SEC-DOCUMENT>0001558370-23-016949.txt : 20231027
<SEC-HEADER>0001558370-23-016949.hdr.sgml : 20231027
<ACCEPTANCE-DATETIME>20231027161952
ACCESSION NUMBER:		0001558370-23-016949
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231027
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231027
DATE AS OF CHANGE:		20231027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		231355839

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>chrs-20231027x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/27/2023 8:07:00 PM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: 11da00a2-e135-4625-8c9e-d6277994a88f -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:chrs="http://www.coherus.com/20231027" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityCentralIndexKey" id="Tc_yRrJZTF5M0qlPfkLSkccFw_2_1">0001512762</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:AmendmentFlag" id="Tc_ohSyNL6akEyXwsnAH_fAyQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="chrs-20231027.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-27</xbrli:startDate><xbrli:endDate>2023-10-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:9.77pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_5d8b359f_3596_4183_b770_860a8dd612f7"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:DocumentType" id="Narr_xejIOMcvokiKAzi1Rxrxfw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_oS96IdFIF0m3RKrXCm_NEg"><b style="font-weight:bold;">October 27, 2023</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:24pt;font-weight:bold;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityRegistrantName" id="Narr_m45EgWEhhk-i1rd2I4FeQg">COHERUS BIOSCIENCES, INC.</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_4fef730f_4ab3_41d5_9b95_011d505ca620"></a><a id="Tc_xhh9hKn_M0az9JtUyNIFvw_1_0"></a><a id="Tc_0Ec6qKzrDEqjU4cWhMTvRg_1_2"></a><a id="Tc_gTVpYaJxOEigG4Nk5jtqZg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_IsxPNymRV0WU0QXE_hpHJg_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityFileNumber" id="Tc_Bb6TcLriNkyVG-REZkjf4A_0_2"><b style="font-size:9pt;font-weight:bold;">001-36721</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityTaxIdentificationNumber" id="Tc_6uAimXKUkk-fXBVR7XyWgw_0_4"><b style="font-size:9pt;font-weight:bold;">27-3615821</b></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br /><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><br /><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityAddressAddressLine1" id="Narr_AeHhMZgmxke1F7Zn4mNE7g"><b style="font-weight:bold;">333 Twin Dolphin Drive</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityAddressAddressLine2" id="Narr_TF_ygz7UHEqcKRi_cEq2Yg"><b style="font-weight:bold;">Suite 600</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityAddressCityOrTown" id="Narr_6CmqTd-9xEKhUYiHhz6nkQ"><b style="font-weight:bold;">Redwood City</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityAddressStateOrProvince" id="Narr_RrgZua9lNESoMLYWer577A"><b style="font-weight:bold;">CA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:EntityAddressPostalZipCode" id="Narr_gCtEkGlwB0eW3VbM_YKf_A"><b style="font-weight:bold;">94065</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:CityAreaCode" id="Narr_MDAlcCsmI0udEbJo1IjE1w"><b style="font-weight:bold;">650</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:LocalPhoneNumber" id="Narr_e-GNjCZQCEeZoHImujx0SA"><b style="font-weight:bold;">649-3530</b></ix:nonNumeric></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_1df92469_f3ff_4402_ae86_b7c37a7d26ea"></a><a id="Tc_JpE3CzrgVUuzIzbndX50BA_0_1"></a><a id="Tc_HwwANRaBU0e9esbgxGxX4A_2_1"></a><a id="Tc_sfUxyqB3w0ei9Xx_ZBZHNg_4_1"></a><a id="Tc_vMBl9mFRdkm9RNXbKk97RA_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_lGV9OliC4k-r7l4nAvpqqg_0_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_QT3N7X93rEKhucm4cLcofQ_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_xM4yiVbfLkG7Vm9kfv8lsA_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_D1Sc1uT9UUqzVeiClU1abQ_6_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_132bb9e4_a733_46a7_a748_975eae4dea5f"></a><a id="Tc_LecPEFtqRkqygHTRSkAbAg_0_0"></a><a id="Tc_6nzrToTmCEWQTr3Vmc4pBw_0_2"></a><a id="Tc_UkDaH23M4EWKlO4ZeHb75g_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b><br /><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange</b><br /><b style="font-weight:bold;">on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:Security12bTitle" id="Tc_SFNRdbaObkSltySCTRexKw_1_0"><b style="font-weight:bold;">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" name="dei:TradingSymbol" id="Tc_wrRjF364gkW4VuP1Ow-mJw_1_2"><b style="font-weight:bold;">CHRS</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_68bM-uwKFUGQPS5Gw7NSmQ_1_4"><b style="font-weight:bold;">The Nasdaq Global Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_dmr1u56idEKBO6SI1wM6MQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:48.95pt;text-align:justify;text-indent:-48.95pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c4dcf4cf_4cff_4c5e_9df2_d9d146fbcea2"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:48.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Item&#160;7.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Regulation FD Disclosure</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">On October 27, 2023, the Company issued a press release announcing that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved LOQTORZI&#8482; (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (&#8220;NPC&#8221;), and for toripalimab, as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">This information in this Item 7.01 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7b84f036_9313_4845_96f4_d1f8fcce5566"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8.01 Other Events</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company plans and projects payment of the $25.0 million milestone due to Shanghai Junshi Biosciences Co., Ltd. (&#8220;Junshi Biosciences&#8221;) pursuant to the Exclusive License and Commercialization Agreement with Junshi Biosciences dated as of February 1, 2021 to occur in March 2024.</p><a id="_e9e602d9_17ea_4fce_8b86_b6c7c7fca16b"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:48.95pt;text-indent:-48.95pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01&#160;&#160;&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:7.3pt;"><td style="vertical-align:top;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:90.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:6.8pt;"><td style="vertical-align:top;width:8.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231027xex99d1.htm"><span style="font-style:normal;font-weight:normal;">Press release dated October 27, 2023</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover page Interactive Data file (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8dcae6ca_c49b_4d45_8b95_0581b247a96b"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.45pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: October 27, 2023</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">COHERUS BIOSCIENCES, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ McDavid Stilwell</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">McDavid Stilwell</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>chrs-20231027xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/27/2023 08:06:58 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="chrs-20231027xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:68.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:124.95pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#0a0a0a;font-size:12pt;font-weight:bold;">Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI&#8482; (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="color:#0a0a0a;font-style:italic;">&#8211;&#160; LOQTORZI is the first and only FDA-approved treatment for NPC &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="color:#0a0a0a;font-style:italic;">&#8211;&#160;Indicated in combination with chemotherapy for 1</i><sup style="color:#0a0a0a;font-size:7.5pt;font-style:italic;vertical-align:top;">st</sup><i style="color:#0a0a0a;font-style:italic;"> line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="color:#0a0a0a;font-style:italic;">&#8211;&#160; Conference today at 4:30 p.m. Eastern Daylight Time &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">REDWOOD CITY, Calif.,&#160;and&#160; SHANGHAI, China, October 27, 2023&#160;--&#160; Coherus BioSciences, Inc.&#160;(&#8220;Coherus&#8221;, NASDAQ: CHRS), and&#160; Shanghai Junshi Biosciences Co., Ltd</font><font style="color:#0a0a0a;font-family:'SimSun';">.</font><font style="color:#0a0a0a;"> (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI&#8482; (toripalimab-tpzi)</font> <font style="color:#0a0a0a;">in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The approval was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study and is irrespective of a patient&#8217;s PD-L1 status. LOQTORZI is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">In the JUPITER-02 Phase 3 study, LOQTORZI combined with chemotherapy significantly improved progression-free survival (PFS), reducing the risk of disease progression or death by 48% compared to chemotherapy alone. LOQTORZI also demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">The safety profile of LOQTORZI was consistent with the PD-1 inhibitor class. </font>The incidence of Grade &#8805;3 adverse events (AEs) (89.7% vs 90.2%) and fatal AEs (3.4% vs 2.8%) was similar between the two arms. AEs leading to discontinuation of LOQTORZI versus placebo (11.6% vs 4.9%), immune-related adverse events (irAEs) (54.1% vs. 21.7%), and Grade &#8805;3 irAEs (9.6% vs. 1.4%) were more frequent in the LOQTORZI arm.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">In the POLARIS-02 clinical study </font><font style="color:#0a0a0a;">LOQTORZI </font><font style="color:#0a0a0a;">demonstrated durable antitumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an objective response rate (ORR) of 20.5%, a disease control rate (DCR) of 40.0%, and a median OS of 17.4 months with an acceptable safety profile.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">NPC is an aggressive cancer that starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with radiation and chemotherapy. LOQTORZI is the first FDA-approved agent for NPC patients.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;white-space:pre-wrap;">  </font><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">&#8220;LOQTORZI&#8217;s first approval is a pivotal event for Coherus as an innovative oncology company. As a next generation PD-1 inhibitor it is the keystone of our I-O strategy to extend cancer patient survival as shown with the impressive results in NPC,&#8221; said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. &#8220;We are particularly excited to now turn our attention to developing LOQTORZI across multiple tumor types in combination with I-O agents that target the tumor microenvironment, such as our IL27-targeted antibody, casdozokitug, and our CCR8 inhibitor CHS-114, potentially greatly expanding the number of cancer patients achieving improved survival benefit.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;font-style:italic;font-weight:bold;"> </font><font style="color:#0a0a0a;">&#8220;Today&#8217;s FDA approval of LOQTORZI is very encouraging for those living with NPC who currently have very limited treatment options and are in need of new therapies to treat this aggressive and life-threatening form of cancer,&#8221; said Jong Chul Park, M.D., Assistant Professor, Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">Hospital Cancer Center. &#8220;LOQTORZI is a new treatment option that has demonstrated the ability to significantly improve PFS and OS and should quickly emerge as the new standard of care when used in combination with chemotherapy.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">The recommended LOQTORZI dose with cisplatin and gemcitabine is 240 mg every three weeks until disease progression, unacceptable toxicity, or up to 24 months. The recommended LOQTORZI dose as a single agent for previously treated NPC is 3 mg/kg every two weeks until disease progression or unacceptable toxicity.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">LOQTORZI is expected to be available in the United States in Q1 2024. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">&#8220;The impressive results from JUPITER-02 and POLARIS-02 have provided conclusive evidence that establishes toripalimab, in combination with chemotherapy or as monotherapy, as the standard therapy for advanced NPC,&#8221; said Professor Ruihua Xu of Sun Yat-sen University Cancer Center, the principal investigator of JUPITER-02 and POLARIS-02. &#8220;This great achievement was only made possible through the solid foundation laid by countless oncology experts over decades of in-depth research, as well as the selfless dedication of the patients and research teams involved in our toripalimab studies. We hope that this promising therapy will close the treatment gap for international NPC patients struggling to find effective therapies, bringing them renewed hope for better survival.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8220;We&#8217;re excited to reach another significant company milestone of &#8216;going overseas&#8217;,&#8221; said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. &#8220;Following etesevimab, toripalimab has become Junshi Biosciences&#8217; second product to receive FDA approval for commercialization&#8212;an achievement that will further enhance the company&#8217;s international presence. Currently, the establishment of toripalimab&#8217;s global commercialization network is in progress, and the network aims to span over 50 countries. In accordance with the company&#8217;s &#8216;In China, For Global&#8217; strategy, we will continue working with our collaborators to promote the commercialization of toripalimab in other regions, in order to provide innovative and high-quality drugs from China to more patients overseas.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#0a0a0a;font-weight:bold;">About JUPITER-02 </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">JUPITER-02 is the largest randomized, double-blind, placebo-controlled, international, multi-center Phase 3 clinical study to evaluate a checkpoint inhibitor plus chemotherapy for the first-line treatment of recurrent or metastatic NPC. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">Two hundred eighty-nine patients with advanced NPC who had received no prior chemotherapy for recurrent/metastatic disease were randomized 1:1 to receive LOQTORZI (toripalimab-tzpi) 240 mg or placebo in combination with gemcitabine 1000 mg/m</font><sup style="color:#0a0a0a;font-size:7.5pt;vertical-align:top;">2</sup><font style="color:#0a0a0a;"> (days 1 and 8) and cisplatin 80 mg/m</font><sup style="color:#0a0a0a;font-size:7.5pt;vertical-align:top;">2 </sup><font style="color:#0a0a0a;">(day 1) of every three-week treatment cycle, followed by toripalimab-tzpi or placebo monotherapy every 3 weeks until disease progression, intolerable toxicity, or completion of two years of treatment. JUPITER-02 included all eligible patients regardless of PD-L1 status and histologies.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">In this study, LOQTORZI met the primary endpoint, demonstrating a significant improvement in PFS (assessed by a Blinded Independent Review Committee (BIRC)) compared to the chemotherapy alone arm with toripalimab-tzpi, reducing the risk of disease progression or death by 48% (HR=0.52 [95% CI: 0.36, 0.74; P&lt;0.0003). Improvement in PFS was observed irrespective of PD-L1 status.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">LOQTORZI demonstrated a statistically significant and clinically meaningful improvement in OS with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone. Median OS has not been reached in the LOQTORZI arm versus 33.7 months for chemotherapy treatment alone (HR=0.63 [95% CI 0.45-0.89]; P=0.0083). </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">LOQTORZI also demonstrated an improvement in ORR, duration of response (DoR), and DCR. In the study, 77% of patients treated with LOQTORZI experienced a complete or partial response (19% and 58% respectively) and the median duration of response was 10 months in the LOQTORZI arm versus 5.7 months in the chemotherapy alone arm.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">About LOQTORZI Solutions </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;">Coherus is committed to supporting patients with programs for zero out-of-pocket costs or patient assistance for eligible patients so that they may benefit from a proven PD-1 immunotherapy, with less financial burden.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Our robust patient support services include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Reimbursement support</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Patient support</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Access support</font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.43;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">Commitment to the NPC community</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Given the limited resources available to patients and caregivers contending with NPC, Coherus has launched a new </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">educational community resource, </font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">NPCFacts.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">, which includes detailed information about the types of NPC as well as its causes, diagnosis, and treatment options.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">In addition to education about nasopharyngeal carcinoma, the website includes links to patient-advocacy organizations providing additional resources, including the Head and Neck Cancer Alliance, Support for People with Oral Head and Neck Cancer, and Thyroid Head and Neck Cancer Foundation. </font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">The website includes a companion website for healthcare professionals treating patients with NPC, including educational resources and opportunities for peer-to-peer education.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">About NPC</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;"><br></b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">NPC is a type of aggressive cancer that starts in the nasopharynx, the upper part of the throat behind the nose and near the base of the skull. NPC is rare in the United States, with an annual incidence of fewer than one per 100,000. The five-year survival rate for all patients diagnosed with NPC is approximately 60%, however, those who are diagnosed with advanced disease have a five-year survival rate of approximately 49%. </font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with radiation and chemotherapy. Patients treated with chemotherapy alone experience poor prognosis: only 20% experience one-year PFS; up to 50% developed distant metastasis during their disease course; and low median OS of 29 months.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI&#8482; is the first FDA-approved therapy for NPC and will represent a new standard of care for treating the disease when used in combination with cisplatin and gemcitabine in the first line setting or as monotherapy in the second line or greater setting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#0a0a0a;font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#0a0a0a;font-weight:bold;">About LOQTORZI&#8482; (</b><b style="font-weight:bold;background:#ffffff;">toripalimab-tpzi)</b></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD</font><font style="font-family:'Tahoma';background:#ffffff;">&#8288;</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">-</font><font style="font-family:'Tahoma';background:#ffffff;">&#8288;</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types. </font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">INDICATIONS AND IMPORTANT SAFETY INFORMATION</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">INDICATIONS</b></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI (toripalimab-tpzi) is indicated:</font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;">As a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.  </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">IMPORTANT SAFETY INFORMATION</b></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Severe and Fatal Immune-Mediated Adverse Reactions</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-line:none;background:#ffffff;"><br></b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions. Immune-mediated adverse reactions, which can be severe or fatal, occur in any organ system or tissue, affect more than one body system simultaneously, and occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment, they can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.</font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Withhold or permanently discontinue LOQTORZI based on severity and type of reaction (see Dosage and Administration in Prescribing Information). In general, If LOQTORZI requires interruption or discontinuation, </font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.</font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Immune-Mediated Pneumonitis</u><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated pneumonitis. </font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated pneumonitis occurred in 2.1% (3/146) of patients, including Grade 2 (1.4%) adverse reactions. Pneumonitis resolved in 67% (2/3) of these patients.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI monotherapy, immune-mediated pneumonitis occurred in 2.6% (22/851) of patients, including fatal (0.2%), Grade 3 (0.7%), and Grade 2 (1.1%) adverse reactions. Systemic corticosteroids were required in 82% (18/22) of patients with pneumonitis. Pneumonitis led to permanent discontinuation of LOQTORZI in 1.2% (10/851) of patients. Pneumonitis resolved in 23% (5/22) of these patients. </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Immune-Mediated Colitis</u><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving LOQTORZI monotherapy, immune-mediated colitis occurred in 0.4% (3/851) of patients, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. Colitis resolved in all 3 patients.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Hepatotoxicity and Immune-Mediated Hepatitis</u><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated hepatitis.</font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated hepatitis occurred in 0.7% (1/146) of patients, which was a Grade 3 (0.7%) adverse reaction. The patient with immune-mediated hepatitis required systemic corticosteroids.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI monotherapy, immune-mediated hepatitis occurred in 3.3% (28/851) of patients, including Grade 4 (0.8%), Grade 3 (2.1%), and Grade 2 (0.4%) adverse reactions. Hepatitis led to permanent discontinuation of LOQTORZI in 1.1% of patients and withholding of LOQTORZI in 0.8% of patients. Hepatitis resolved in 54% (15/28) of these patients. </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Immune-Mediated Endocrinopathies</u><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">Adrenal Insufficiency</i><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity. In patients receiving LOQTORZI monotherapy, adrenal insufficiency occurred in 0.5% (4/851) of patients, including Grade 2 (0.4%) and Grade 1 (0.1%) adverse reactions. Systemic corticosteroids were required in 75% (3/4) of the patients with adrenal insufficiency. Adrenal insufficiency led to withholding of LOQTORZI in 0.1% (1/851) of patients. In the one patient in whom LOQTORZI was withheld, LOQTORZI was reinitiated after symptom improvement.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">Hypophysitis</i><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effects such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue LOQTORZI depending on severity. In patients receiving LOQTORZI monotherapy, hypophysitis occurred in 0.4% (3/851) of patients receiving LOQTORZI, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. All three patients received systemic corticosteroids. Hypophysitis led to permanent discontinuation of LOQTORZI in 0.1% (1/851) of patients and withholding of LOQTORZI in 0.1% (1/851) of patients. The one patient in whom LOQTORZI was withheld reinitiated LOQTORZI.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">Thyroid Disorders</i><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity. </font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, thyroiditis occurred in 2.1% (3/146) of patients receiving LOQTORZI, including Grade 2 (1.4%). Three patients required thyroid hormone replacement therapy. Thyroiditis resolved in one of the 3 patients. Hyperthyroidism occurred in 1.4% (2/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine. Hyperthyroidism resolved in these 2 patients. Hypothyroidism occurred in 30% (44/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine, including Grade 2 (24%) and Grade 1 (6%). Eighty percent of the 44 patients required thyroid hormone replacement therapy. LOQTORZI was withheld in 2.1% (3/146) of the patients. Of the 3 patients in whom LOQTORZI was withheld, 2 patients reinitiated LOQTORZI.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI monotherapy, thyroiditis occurred in 0.6% (5/851) patients receiving LOQTORZI, including Grade 2 (0.1%). Two of these 5 patients received systemic corticosteroids and 2 required thyroid hormone replacement therapy. Thyroiditis resolved in 2 of the 5 patients. Hyperthyroidism occurred in 7% (55/851) of patients receiving LOQTORZI, including Grade 2 (1.9%). Hyperthyroidism resolved in 85% (47/55) of the patients. Hypothyroidism occurred in 15% (128/851) of patients receiving LOQTORZI, including Grade 2 (8%). Sixty three percent of the 128 patients required thyroid hormone replacement therapy. LOQTORZI was withheld in 0.5% of patients. Of the 4 patients in whom LOQTORZI was withheld, 3 patients reinitiated LOQTORZI. </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">Type 1 Diabetes Mellitus, which can present with Diabetic Ketoacidosis</i><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity. In patients receiving LOQTORZI monotherapy, diabetes mellitus occurred in 0.9% (8/851) of patients receiving LOQTORZI, including Grade 4 (0.1%), Grade 3 (0.7%), and Grade 2 (0.1%). Diabetes mellitus led to permanent discontinuation in 0.4% of patients. Six of the 8 (75%) patients with diabetes mellitus required long-term insulin therapy.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Immune-Mediated Nephritis with Renal Dysfunction</u><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated nephritis. </font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated nephritis occurred in 0.7% (1/146) of patients receiving LOQTORZI. The one patient with immune-mediated nephritis (Grade 4) required systemic corticosteroids and nephritis led to discontinuation of LOQTORZI. Nephritis resolved in this patient.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI monotherapy, immune-mediated nephritis occurred in 0.5% (4/851) of patients, including Grade 3 (0.5%) adverse reactions. Nephritis resolved in 75% (3/4) of these patients. </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Immune-Mediated Dermatologic Adverse Reactions</u><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue LOQTORZI depending on severity.</font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated dermatologic adverse reactions occurred in 8% (12/146) of patients, including Grade 3 (3.4%) and Grade 2 (1.4%) adverse reactions. Systemic corticosteroids were required in 25% (3/12) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions led to permanent discontinuation of LOQTORZI in 2.1% (3) of patients. Immune-mediated dermatologic adverse reactions resolved in 92% (11/12) of these patients.</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">5</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI monotherapy, immune-mediated dermatologic adverse reactions occurred in 4% (34/851) of patients, including Grade 3 (0.4%) and Grade 2 (1.4%) adverse reactions. Immune-mediated dermatologic adverse reactions led to withholding of LOQTORZI in 0.4% (3) of the patients. Systemic corticosteroids were required in 12% (4/34) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions resolved in 71% (24/34) of these patients.</font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Other Immune-Mediated Adverse Reactions</u><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">The following clinically significant immune-mediated adverse reactions occurred at an incidence of &lt;1% (unless otherwise noted) in patients who received LOQTORZI or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.</font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Cardiac/Vascular:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Myocarditis, pericarditis, vasculitis, pericardial effusion</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Nervous System:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barr&#233; syndrome, nerve paresis, autoimmune neuropathy</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Ocular:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Gastrointestinal:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Musculoskeletal and Connective Tissue:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica, dermatomyositis</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Endocrine:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Hypoparathyroidism</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;background:#ffffff;">Hematologic/Immune:</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Infusion-Related Reactions</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause severe or life-threatening infusion-related reactions including hypersensitivity and anaphylaxis.</font></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, infusion-related reactions have been reported in 4.1% of patients, including Grade 2 (0.7%) reactions.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In patients receiving LOQTORZI monotherapy, infusion-related reactions occurred in 2% of 851 patients, including Grade 3 (0.1%) and Grade 2 (0.6%). LOQTORZI was withheld for one Grade 3 infusion related reaction. Monitor patients for signs and symptoms of infusion-related reactions including rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. For severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue LOQTORZI. </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Complications of Allogeneic Hematopoietic Stem Cell Transplant (HSCT)</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Embryo-Fetal Toxicity</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">LOQTORZI can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LOQTORZI and for 4 months after the last dose.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Lactation</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">There are no data on the presence of toripalimab-tpzi in human milk; its effects on the breastfed child, or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to toripalimab-tpzi are unknown. Because of the potential for serious adverse reactions in breastfed children, advise lactating women not to breastfeed during treatment with LOQTORZI and for 4 months after the last dose.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Serious Adverse Reactions</b></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;">In JUPITER-02, when LOQTORZI was administered in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma, serious adverse reactions occurred in 43% of patients. Serious adverse drug reactions in &#8805;2% were thrombocytopenia (14%), neutrophil count decreased (10%), pneumonia (10%), anemia (9%), abnormal hepatic function (2.7%), and rash (2.1%). There were three fatal adverse reactions (2.1%): one due to epistaxis; one due to intracranial hemorrhage associated with immune-related thrombocytopenia and coagulopathy; and one due to pneumonia. Permanent discontinuation of LOQTORZI, due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation of LOQTORZI in &#8805;1% were pneumonia (2.1%), pulmonary tuberculosis (1.4%), rash (1.4%), and vomiting (1.4%).  The most common Grade 3 to 4 laboratory abnormalities (&#8805;2%) were decreased neutrophils (58%), decreased lymphocytes (57%), decreased hemoglobin (50%) decreased platelets (33%), decreased potassium (10%), decreased sodium (9%), increased alanine aminotransferase (6%), increased or decreased magnesium (4.2% each), decreased calcium (3.5%), increased aspartate aminotransferase (2.7%), increased bilirubin (2.1%).</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In POLARIS-02, when LOQTORZI was administered as a single agent to patients with previously treated, unresectable or metastatic nasopharyngeal carcinoma, serious adverse reactions occurred in 24% of patients. Serious adverse drug reactions in &#8805;2% were pneumonia (4.7%), abnormal hepatic function (2.6%), and hyperbilirubinemia (2.1%). Fatal adverse reactions occurred in 3.7% of patients who received LOQTORZI, including death not otherwise specified (1.6%), tumor hemorrhage (0.5%), hepatic failure and thrombocytopenia (0.5%), hyponatremia (0.5%), and sudden death (0.5%). Permanent discontinuation of LOQTORZI due to an adverse reaction occurred in 9% of patients. Adverse reaction resulting in permanent discontinuation of LOQTORZI in &#8805;1% included pneumonia (1.1%), abnormal hepatic function (1.1%), and hyperbilirubinemia (1.1%). The most common Grade 3 or 4 laboratory abnormalities (&#8805;2%), were decreased sodium (11%), decreased lymphocytes (9%), decreased hemoglobin (6%), increased aspartate aminotransferase (3.8%), decreased phosphate (3.2%), and increased alkaline phosphatase (2.2%).</font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Common Adverse Reactions</b></p><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In JUPITER-02, the most common adverse reactions (&#8805;20%) were nausea (71%), vomiting (68%), decreased appetite (55%), constipation (39%), hypothyroidism (38%), rash (36%), pyrexia (32%), diarrhea (31%), peripheral neuropathy (30%), cough (26%), musculoskeletal pain (25%), upper respiratory infection (23%), insomnia (23%), dizziness (21%), and malaise (21%).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In POLARIS-02, in patients with previously treated, unresectable or metastatic nasopharyngeal carcinoma, the most common (&#8805;20%) adverse reactions were hypothyroidism (27%), fatigue (22%), and cough (20%). </font></td></tr></table><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Please see </font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Prescribing Information</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"> for LOQTORZI and </font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Medication Guide</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">Conference Call Information</b></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">When: Friday, October 27, 2023, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">7</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI5e94411d336341ba89d7e9eed804e892</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Please dial-in 15 minutes early to ensure a timely connection to the call.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Webcast Link: </font><font style="font-size:12pt;">https://edge.media-server.com/mmc/p/hpvx6oka</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">A replay of the webcast will be archived on the &#8220;Investors&#8221; section of the Coherus website at http://investors.coherus.com.</font></p><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.43;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">About Coherus BioSciences</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that will be synergistic with its proven commercial capabilities in oncology.</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Coherus&#8217; immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 is a highly selective, competitively positioned, ADCC-enhanced anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors. </font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Coherus&#8217; earlier-stage immuno-oncology pipeline targets immune-suppressive mechanisms, including CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 clinical trial in combination with LOQTORZI in patients with advanced solid tumors, and CHS-1000, a preclinical program targeting the novel pathway ILT4.</font></p><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Coherus markets UDENYCA&#174; (pegfilgrastim-cbqv), a biosimilar of Neulasta&#174;, CIMERLI&#174; (ranibizumab-eqrn), a biosimilar of Lucentis&#174;, YUSIMRY&#8482; (adalimumab-aqvh), a biosimilar of Humira&#174; and expects to launch LOQTORZI (toripalimab-tpzi), a novel next generation PD-1 inhibitor, in the U.S. in Q1 2024.</font></p><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.43;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">About Junshi Biosciences</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&amp;D pipeline comprising more than 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. </font><font style="font-family:'Calibri','Helvetica','sans-serif';">Four of the company&#8217;s innovations have already reached the Chinese or international markets, one of which is China&#8217;s first self-developed anti-PD-1 monoclonal antibody, toripalimab. Additionally, more than 30 drugs are currently in clinical development. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI&#174;, and other novel therapies for the prevention and treatment of COVID-19. </font></p><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">With a mission of &#8220;providing patients with world-class, trustworthy, affordable, and innovative drugs&#8221;, Junshi Biosciences is &#8220;In China, For Global.&#8221; At present, the company has approximately 3,000 employees in the United States (California and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: </font><font style="font-family:'Calibri','Helvetica','sans-serif';">http://junshipharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">. </font></p><p style="font-family:'Helvetica Neue';font-size:12pt;line-height:14pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;line-height:1.43;margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:14pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">Forward-Looking Statements</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding Coherus&#8217; ability to achieve synergies between its I-O pipeline and its commercial capabilities; Coherus&#8217; expectations for the selectivity and competitive positioning of any of its product candidates; Coherus&#8217; expectations that LOQTORZI</i><i style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">&#8482; will represent the new standard of care for NPC; Coherus&#8217; </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:14pt;margin:0pt 0pt 6pt 0pt;"><i style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">projected timing for commercial availability of </i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">LOQTORZI</i><i style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">&#8482;; Coherus&#8217; expectations for the development of LOQTORZI&#8482; in combination with I-O agents that target the tumor microenvironment; and </i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;background:#ffffff;">Coherus&#8217; ability to gain approval for any of its product candidates and the timing of such approval. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus&#8217; actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of the drug development position of Coherus&#8217; competitors; the risks and uncertainties of the integration process following Coherus&#8217; acquisition of Surface Oncology, Inc.; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus&#8217; business; the timing of Coherus&#8217; regulatory filings; the risk of FDA review issues; the risk of Coherus&#8217; execution of its change in strategy from a focus on biosimilars to a strategy using cash from its portfolio to fund an oncology franchise; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus&#8217; drug candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus&#8217; business in general, see Coherus&#8217; Quarterly Report on Form 10-Q the quarter ended June 30, 2023, filed with the Securities and Exchange Commission on August 2, 2023, including the section therein captioned &#8220;Risk Factors&#8221; and in other documents Coherus files with the Securities and Exchange Commission. </i></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:14pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">Coherus Contact Information</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Investors:</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Jodi Sievers, VP Corporate Communications</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">IR@coherus.com</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:14pt;margin:8pt 0pt 6pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Media:</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Judy Stecker, Hill &amp; Knowlton</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Senior Vice President, U.S. Healthcare Media and Public Affairs Lead</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">judy.stecker@hkstrategies.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">+1 202 559 7245 &#8212; direct</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:14pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">Junshi Biosciences Contact Information</b><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">IR Team:</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">info@junshipharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">+ 86 021-6105 8800</font></p><p style="font-family:'Helvetica Neue';font-size:11pt;line-height:14pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">PR Team:</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">Zhi Li</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">zhi_li@junshipharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">+ 86 021-6105 8800</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">9</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>chrs-20231027xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20231027xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "* /H# 2(  A$! Q$!_\0
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MQ,\C-G& H&:_2O\ 8Z_9>;X*Z/-K_B&.-O%^HQ"-HU(86,.0?*![L2 6(XX
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M<5ZS\*M$U#PS\,_">D:LJ)J5AI5K:W*QMN42)$JL >_(ZUU/6O.OV@OB_:_
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MWMTSD#+L[DD$?(*]@3_@FPND?&S0I+?4&U7X=!C<W@NV47*%,$0-C <2' W
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M?B-,#GB3Q!N_G'6%J/\ P3@^&NKW)N+[7O%]Y.0%,MQJ44C8],F$FM']F/\
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MW?;^^./S K[^K\^/^"66LV\.H?$'3'<+<RQ6=PBD\LBF56('L77\Z_08'(H
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M)DMRVXPRJ2LB9[X8$ ]Q@UW%?(_P)^(%A^R[^SAX)T_Q;;7K:IJ"RWYL[:-
MUO%-*S(96D=%3.5 !;).<#Y6QZXO[5/PXC4)>ZS/IUXHQ-9W5A.LL#_Q1N A
M 93D$ GD'F@#URO.OBO^S]X$^--L$\5:#!>72+MBOXLQ7,8]!(O)'L<CVKT6
MB@#XA\0_\$N?#5W<;]$\:ZGID623'>6<=R?;#*R8Q]#5GPI_P3 \)Z==++XA
M\6ZIKD:L"(+6!+12.X8DN?RQ7VK10!S/P^^&OAKX6:!%HOA?2+?2-/3DI"OS
M2-_>=C\SM[DFNFHHH \>^-G[*G@#X[-]KUW3GM-:";%U?3F$5Q@= W!5P/\
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M6CO6EV\E BJ"#CIZD@5B:=\8/B1-#8:O<_":X/A^],;!;+5H9M0AC?&'DM\
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(FD'04M '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>chrs-20231027.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/27/2023 8:07:04 PM-->
<!--Modified on: 10/27/2023 8:07:04 PM-->
<xsd:schema targetNamespace="http://www.coherus.com/20231027" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:chrs="http://www.coherus.com/20231027">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231027_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231027_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231027_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="chrs_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>chrs-20231027_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/27/2023 8:07:04 PM-->
<!--Modified on: 10/27/2023 8:07:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="chrs-20231027.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>chrs-20231027_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/27/2023 8:07:04 PM-->
<!--Modified on: 10/27/2023 8:07:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="chrs-20231027.xsd#chrs_DocumentAndEntityInformationAbstract" xlink:label="chrs_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="chrs_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>chrs-20231027_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/27/2023 8:07:04 PM-->
<!--Modified on: 10/27/2023 8:07:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="chrs-20231027.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20231027.xsd#chrs_DocumentAndEntityInformationAbstract" xlink:label="chrs_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638340340243287870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638340340243287870" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638340340243287870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638340340243287870" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638340340243287870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638340340243287870" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638340340243297882" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638340340243297882" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638340340243297882" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638340340243297882" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638340340243297882" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638340340243297882" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638340340243297882" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638340340243297882" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638340340243297882" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638340340243297882" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638340340243297882" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638340340243297882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638340340243297882" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638340340243307848" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638340340243307848" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638340340243307848" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638340340243307848" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638340340243307848" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638340340243307848" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638340340243307848" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638340340243307848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638340340243307848" order="23" use="optional" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140608050803968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COHERUS BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 27,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>chrs-20231027x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="chrs-20231027.xsd" xlink:type="simple"/>
    <context id="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2023-10-27</startDate>
            <endDate>2023-10-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_yRrJZTF5M0qlPfkLSkccFw_2_1">0001512762</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_ohSyNL6akEyXwsnAH_fAyQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_xejIOMcvokiKAzi1Rxrxfw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_oS96IdFIF0m3RKrXCm_NEg">2023-10-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_m45EgWEhhk-i1rd2I4FeQg">COHERUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_IsxPNymRV0WU0QXE_hpHJg_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_Bb6TcLriNkyVG-REZkjf4A_0_2">001-36721</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_6uAimXKUkk-fXBVR7XyWgw_0_4">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_AeHhMZgmxke1F7Zn4mNE7g">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_TF_ygz7UHEqcKRi_cEq2Yg">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_6CmqTd-9xEKhUYiHhz6nkQ">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_RrgZua9lNESoMLYWer577A">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_gCtEkGlwB0eW3VbM_YKf_A">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_MDAlcCsmI0udEbJo1IjE1w">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_e-GNjCZQCEeZoHImujx0SA">649-3530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_lGV9OliC4k-r7l4nAvpqqg_0_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_QT3N7X93rEKhucm4cLcofQ_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_xM4yiVbfLkG7Vm9kfv8lsA_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_D1Sc1uT9UUqzVeiClU1abQ_6_0">false</dei:PreCommencementTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_SFNRdbaObkSltySCTRexKw_1_0">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_wrRjF364gkW4VuP1Ow-mJw_1_2">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Tc_68bM-uwKFUGQPS5Gw7NSmQ_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng"
      id="Narr_dmr1u56idEKBO6SI1wM6MQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'F"6U<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !Y@EM7VJMT6.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O;1%Q=#E9<,G!<&!XEM(;EM8TX3DI-VWMXU;A^@'\#%W__SN
M=W"M#D+[B"_1!XQD,=V,KNN3T&'%#D1! "1]0*=2.27ZJ;GST2F:GG$/0>FC
MVB/4G-^!0U)&D8(96(2%R&1KM- 1%?EXQAN]X,-G[#+,:, .'?:4H"HK8'*>
M&$YCU\(5,,,(HTO?!30+,5?_Q.8.L'-R3'9)#<-0#DW.33M4\/[\])K7+6R?
M2/4:IU_)"CH%7+'+Y+=FO=D^,EGSNBDJ7M3WVYJ+ZD'<\H_9]8??5=AY8W?V
M'QM?!&4+O^Y"?@%02P,$%     @ >8);5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%[8!/-]*:=XJ]KA>_=LR^1M02P,$%     @ >8);5Y^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ >8);5P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !Y
M@EM7VJMT6.\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !Y@EM7F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'F"6U<])(C6
M=00  'D1   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !Y@EM7GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"   9%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="chrs-20231027x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chrs-20231027.xsd</File>
    <File>chrs-20231027_def.xml</File>
    <File>chrs-20231027_lab.xml</File>
    <File>chrs-20231027_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="chrs-20231027x8k.htm">chrs-20231027x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "chrs-20231027x8k.htm": {
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20231027",
   "dts": {
    "schema": {
     "local": [
      "chrs-20231027.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "chrs-20231027_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20231027_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20231027_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "chrs-20231027x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231027x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_27_2023_To_10_27_2023_87hlT2C-IUyx7IIB7BoJng",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231027x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "chrs_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231027",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-016949-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-016949-xbrl.zip
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M %W.F"I"593>C1$=\EO=/RB9L5&;C"<!7AA'PZ2VG='2*HN(:J4V$UJ>\(&
M*G/(W"&WKXK.-N*W#T%RCR,T_Q.9N7RKLYU(0V5%%M=$-E-H2O5 _G);D+[
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M2\7DYK3I0F"AH5"\.CWI&'WB8L[VP@A[QA04>QQQ,/6Y)S-4V!Y 0BCRBU&
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MUS@@&+C=)%6TO0$YH$JI!D/>X?S3_9ICU$.WR<=F0__J"\V?#6%9M4RYM-A
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MS8&KMEM7^O% 5=HUK3QM^;K74%:*HC>Q5K+YE1'=]QT=@YA$(*QYG?T]L"-
M.<VHQ%X:8X?39*1S^$T]<^RZ/. "Q9&]VLWP^CI;";DG!QD^.J3G$W391)V)
M"ZK\ Y,"59'EF10\.:D](Y"Z<0JE. +2Y)&$AKF*MW8,?"^+I50YW2DEHQ5D
MVX*"Z@=M)$I\ 1I^O)>"?:7<^=O:[O72]9GF]KKI]Z+:I>,[M@$RX/5.P5$
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MHI]R\>CXX/+PXKQ3.APIK8Y[D>[4>]2I@'BFA4,37Z-#QX?0'9WB8$"B%79
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MJD )$PP^)O8\,$D&=0JC/H[8(Y>%3@$=T'V X"6B_2#NH9KIVAYS5QERMJF
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MUN!?P7K*&:F6I'CHH"1/:A1)CI6Q+8VD))-O:VL+[ ;9&'4W.GU0HG_]OO<
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M*4)F4*6_JX=Y]:<\B1*B.L"X1%R"C.'_]_7?%:QUE*_BH[]U.?ZW/&(?'FQ
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M<*/Q-QD$&:!4,@,^'0"M,([K!\%.,]VAY4P(D04J[K!OR!Y?*M.^")=B7ZM
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M_QYS_ZQ3:NA<;\ &2?VHZ&WH)[@TX/BRM,/Y?GCEC@_83Z!-P<$5NMZ][S%
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M'WL+NPRH28!TPZQ23+4WL07M)[5M"))B4W5G8/G8Z!WV*  VD@?&"?;R,',
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M0,G!1KH3)<[!$YU_@1$A8]/6TR:+B):U@%/4W]W,$:2>QS*Y(R,_=^^BLQ
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MRN\ M!!H?N1;BPU;"$9ZA)C0AS))9DMY'3J7 "VRF#;<I7J2J)P<6.+#JTN
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M     &-H<G,M,C R,S$P,C<N>'-D4$L! A0#%     @ >8);5P9L.KXG P
M60P  !4              ( !;@0  &-H<G,M,C R,S$P,C=?9&5F+GAM;%!+
M 0(4 Q0    ( 'F"6U?<?R2UH 4  )0^   5              "  <@'  !C
M:')S+3(P,C,Q,#(W7VQA8BYX;6Q02P$"% ,4    " !Y@EM7M?M7--$$   Q
M+   %0              @ &;#0  8VAR<RTR,#(S,3 R-U]P<F4N>&UL4$L!
M A0#%     @ >8);5PS_@Y7)%@  Z*$  !0              ( !GQ(  &-H
M<G,M,C R,S$P,C=X.&LN:'1M4$L! A0#%     @ >8);5VI\0&P<.   (5X!
M !@              ( !FBD  &-H<G,M,C R,S$P,C=X97@Y.60Q+FAT;5!+
4!08     !@ & ) !  #L80     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
